MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - pharmaceuticals
- ASTRAZENECA PHARMA - DIVIS LABORATORIES
ASTRAZENECA PHARMA vs DIVIS LABORATORIES - Comparison Results
ASTRAZENECA PHARMA 
Change
AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More
DIVIS LABORATORIES
Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More
Current Valuations
| ASTRAZENECA PHARMA | DIVIS LABORATORIES | ASTRAZENECA PHARMA/ DIVIS LABORATORIES |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 87.7 | 31.9 | 274.9% | View Chart |
| P/BV | x | 19.3 | 7.2 | 269.1% | View Chart |
| Dividend Yield | % | 0.0 | 0.6 | - |
Financials
 ASTRAZENECA PHARMA  DIVIS LABORATORIES |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| ASTRAZENECA PHARMA Mar-18 |
DIVIS LABORATORIES Mar-18 |
ASTRAZENECA PHARMA/ DIVIS LABORATORIES |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,278 | 1,142 | 111.9% | |
| Low | Rs | 883 | 533 | 165.6% | |
| Sales per share (Unadj.) | Rs | 228.4 | 146.6 | 155.8% | |
| Earnings per share (Unadj.) | Rs | 10.4 | 33.0 | 31.4% | |
| Cash flow per share (Unadj.) | Rs | 16.3 | 38.4 | 42.3% | |
| Dividends per share (Unadj.) | Rs | 0 | 10.00 | 0.0% | |
| Dividend yield (eoy) | % | 0 | 1.2 | 0.0% | |
| Book value per share (Unadj.) | Rs | 98.8 | 222.8 | 44.3% | |
| Shares outstanding (eoy) | m | 25.00 | 265.47 | 9.4% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 4.7 | 5.7 | 82.8% | |
| Avg P/E ratio | x | 104.2 | 25.3 | 411.2% | |
| P/CF ratio (eoy) | x | 66.4 | 21.8 | 304.7% | |
| Price / Book Value ratio | x | 10.9 | 3.8 | 291.0% | |
| Dividend payout | % | 0 | 30.3 | 0.0% | |
| Avg Mkt Cap | Rs m | 27,008 | 222,318 | 12.1% | |
| No. of employees | `000 | 1.4 | 10.8 | 12.6% | |
| Total wages/salary | Rs m | 1,535 | 4,561 | 33.7% | |
| Avg. sales/employee | Rs Th | 4,210.9 | 3,616.0 | 116.5% | |
| Avg. wages/employee | Rs Th | 1,132.2 | 423.8 | 267.2% | |
| Avg. net profit/employee | Rs Th | 191.1 | 814.9 | 23.4% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 5,710 | 38,915 | 14.7% | |
| Other income | Rs m | 123 | 1,134 | 10.8% | |
| Total revenues | Rs m | 5,833 | 40,049 | 14.6% | |
| Gross profit | Rs m | 463 | 12,617 | 3.7% | |
| Depreciation | Rs m | 147 | 1,425 | 10.3% | |
| Interest | Rs m | 0 | 13 | 0.0% | |
| Profit before tax | Rs m | 438 | 12,313 | 3.6% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 179 | 3,543 | 5.0% | |
| Profit after tax | Rs m | 259 | 8,770 | 3.0% | |
| Gross profit margin | % | 8.1 | 32.4 | 25.0% | |
| Effective tax rate | % | 40.8 | 28.8 | 141.9% | |
| Net profit margin | % | 4.5 | 22.5 | 20.1% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 3,209 | 45,351 | 7.1% | |
| Current liabilities | Rs m | 2,070 | 6,507 | 31.8% | |
| Net working cap to sales | % | 20.0 | 99.8 | 20.0% | |
| Current ratio | x | 1.6 | 7.0 | 22.3% | |
| Inventory Days | Days | 72 | 127 | 57.1% | |
| Debtors Days | Days | 35 | 95 | 36.7% | |
| Net fixed assets | Rs m | 790 | 21,160 | 3.7% | |
| Share capital | Rs m | 50 | 531 | 9.4% | |
| "Free" reserves | Rs m | 2,419 | 58,625 | 4.1% | |
| Net worth | Rs m | 2,469 | 59,156 | 4.2% | |
| Long term debt | Rs m | 0 | 0 | - | |
| Total assets | Rs m | 4,605 | 67,832 | 6.8% | |
| Interest coverage | x | NM | 926.8 | - | |
| Debt to equity ratio | x | 0 | 0 | - | |
| Sales to assets ratio | x | 1.2 | 0.6 | 216.1% | |
| Return on assets | % | 5.6 | 12.9 | 43.4% | |
| Return on equity | % | 10.5 | 14.8 | 70.8% | |
| Return on capital | % | 17.7 | 20.8 | 85.1% | |
| Exports to sales | % | 0 | 0 | - | |
| Imports to sales | % | 0 | 21.8 | 0.0% | |
| Exports (fob) | Rs m | NA | NA | - | |
| Imports (cif) | Rs m | NA | 8,485 | 0.0% | |
| Fx inflow | Rs m | 300 | 32,359 | 0.9% | |
| Fx outflow | Rs m | 2,015 | 9,042 | 22.3% | |
| Net fx | Rs m | -1,715 | 23,317 | -7.4% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 88 | 7,759 | 1.1% | |
| From Investments | Rs m | -94 | -4,783 | 2.0% | |
| From Financial Activity | Rs m | NA | -3,142 | 0.0% | |
| Net Cashflow | Rs m | -6 | -166 | 3.4% | |
Share Holding
| Indian Promoters | % | 0.0 | 52.0 | - | |
| Foreign collaborators | % | 75.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 0.3 | 11.8 | 2.5% | |
| FIIs | % | 15.7 | 19.0 | 82.6% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 9.1 | 17.2 | 52.9% | |
| Shareholders | 12,856 | 31,796 | 40.4% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ASTRAZENECA PHARMA With: PLETHICO PHARMA BIOCON FULFORD INDIA ALKEM LABORATORIES ELDER PHARMA
Compare ASTRAZENECA PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Indian Indices End on a Strong Note; Sensex Ends 489 Points Higher(Closing)
After opening the day marginally lower, Indian share markets witnessed most of the buying interest during closing hours and ended their trading session on a strong note.
Related Views on News
ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)
May 27, 2019 | Updated on May 27, 2019For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
DIVIS LABORATORIES Announces Quarterly Results (4QFY19); Net Profit Up 10.6% (Quarterly Result Update)
May 27, 2019 | Updated on May 27, 2019For the quarter ended March 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 10.6% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)
Mar 29, 2019 | Updated on Mar 29, 2019Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.
ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)
Feb 12, 2019 | Updated on Feb 12, 2019For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
DIVIS LABORATORIES Announces Quarterly Results (3QFY19); Net Profit Up 68.9% (Quarterly Result Update)
Feb 4, 2019 | Updated on Feb 4, 2019For the quarter ended December 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 68.9% YoY). Sales on the other hand came in at Rs 13 bn (up 29.4% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
More Views on NewsMost Popular
7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)
Jun 13, 2019We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?
The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)
Jun 11, 2019One chart that predicted the NBFC crisis back in 2016.
Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)
Jun 12, 2019This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.
Why Modi 2.0 Will Be Great for These 7 Stocks(Profit Hunter)
Jun 10, 2019The government's focus on Infra, electricity, water for all will be the key factors for Sensex 1,00,000.
Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)
Jun 14, 2019Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.
More|
| |
ASTRAZENECA PHARMA SHARE PRICE
Jun 20, 2019 03:35 PM
TRACK ASTRAZENECA PHARMA
- Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ASTRAZENECA PHARMA
ASTRAZENECA PHARMA 5-YR ANALYSIS
COMPARE ASTRAZENECA PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.